6th The Awaji International Forum on Infection and Immunity  
home english

Lewis L. Lanier, Ph.D.

University of California San Francisco
Department Microbiology and Immunology
Dept. of Microbiology & Immunology


Ph.D. Microbiology and Immunology, University of North Carolina -Chapel Hill, 1978
B.S. Biology (Microbiology), graduated with High Honors, Virginia Polytechnic Institute and State University, 1975


Vice Chair, Department of Microbiology and Immunology, University of California San Francisco, 2003-present

Professor, Department of Microbiology and Immunology and the Cancer Research Institute, University of California San Francisco, 1999-present

Director, Department of Immunobiology, DNAX Research Institute for Molecular and Cellular Biology, 1997-1999

Associate Director, Department of Human Immunology, DNAX Research Institute for Molecular and Cellular Biology, 1993-1996

Senior Scientist, Department of Immunology, DNAX Research Institute for Molecular and Cellular Biology, Inc., 1991-1993

Becton Dickinson Research Fellow and Associate Research Director, Becton Dickinson Immunocytometry Systems, 1990-1991

Associate Research Director, Becton Dickinson Immunocytometry Systems, l988-1991

Senior Research Scientist, Becton Dickinson Monoclonal Center, Inc., 1981-1988

Research Assistant Professor, Department of Pathology, University of New Mexico School of Medicine, 1981

Postdoctoral Fellow, supported by Damon Runyon-Walter Winchell Cancer Fund, University of New Mexico School of Medicine, Department of Pathology, 1979-1981

Postdoctoral Fellow, supported by NIH Training Grant, University of North Carolina Cancer Research Center at Chapel Hill, 1978-1979

Selected publications (recent 5 years)

265. Lanier, L.L. and A. Aderem. 2002. Innate Immunity. Curr. Opin. Immunol. 14:85-86.
266. Masuda, H., Y. Saeki, M. Nomura, K. Shida, M. Matsumoto, M. Ui, L.L. Lanier, and T. Seya. 2002. High levels of RAE-1 isoforms on mouse tumor cell lines assessed by anti-'pan' RAE-1 antibody confer tumor susceptibility to NK cells. Biochem. Biophys. Res. Commun. 290:140-145.
267. Cerwenka, A., C.A. O'Callaghan, J.A. Hamerman, R. Yadav, W. Ajayi, D.C. Roopenian, S. Joyce, and L.L. Lanier. 2002. Cutting Edge: The minor histocompatibility antigen H60 peptide interacts with both H-2Kb and NKG2D. J. Immunol. 168:3131-3134.
268. Naper, C., S. Hayashi, L. Kveberg, E.C. Niemi, L.L. Lanier, J.T. Vaage, and J.C. Ryan. 2002. Ly-49s3 is a promiscuous activating rat NK cell receptor for nonclassical MHC class I-encoded target ligands. J. Immunol. 169:22-30.
269. Arase, H., and L.L. Lanier. 2002. Viral-driven evolution of natural killer cell receptors. Microbes Infect. 4:1505-1512.
270. Arase, H., E.S. Mocarski, A.E. Campbell, A.B. Hill, and L.L. Lanier. 2002. Direct recognition of cytomegalovirus by activating and inhibitory NK cell receptors. Science 296:1323-1326.
271. Ogasawara, K., S.K. Yoshinaga, and L.L. Lanier. 2002. Inducible costimulator costimulates cytotoxic activity and IFN- production in activated murine NK cells. J. Immunol. 169:3676-3685.
272. Lodoen, M., K. Ogasawara, J.A. Hamerman, H. Arase, J.P. Houchins, E.S. Mocarski, and L.L. Lanier. 2003. NKG2D-mediated natural killer cell protection against cytomegalovirus is impaired by viral gp40 modulation of retinoic acid early inducible 1 gene molecules. J. Exp. Med. 197:1245-1253.
273. Michaelsson, J., C. Teixeira de Matos, A. Achour, L.L. Lanier, K. Karre, and K. Soderstrom. 2002. A signal peptide derived from hsp60 binds HLA-E and interferes with CD94/NKG2A recognition. J. Exp. Med. 196:1403-1414.
274. Ogasawara, K., J.A. Hamerman, H. Hsin, S. Chikuma, H. Bour-Jordon, T. Chen, T. Pertel, C. Carnaud, J.A. Bluestone and L.L. Lanier. 2003. Impairment of NK cell function by NKG2D modulation in NOD mice. Immunity 18:41-51.
275. Lanier, L.L. 2003. Natural killer cell receptor signaling. Curr. Opin. Immunol. 15:308-314.
276. Cerwenka, A., and L.L. Lanier. 2003. NKG2D ligands: unconventional MHC class I-like molecules exploited by viruses and cancer. Tissue Antigens 61:335-343.
277. Westgaard, I.H., E. Dissen, K.M. Torgensen, S. Lazetic, L.L. Lanier, J.H. Phillips, and S. Fossum. 2003. The lectin-like receptor KLRE1 inhibits natural killer cell cytotoxicity. J. Exp. Med. 197:1551-1561.
278. Wu, J., and L.L. Lanier. 2003. NK cells and cancer. Adv. Cancer Research 90:127-156.
279. Humphrey, M.B., K. Ogasawara, W. Yao, S.C. Spusta, M.R. Daws, N.E. Lane, L.L. Lanier, and M.C. Nakamura. 2004. The signaling adapter protein DAP12 regulates multinucleation during osteoclast development. J. Bone Miner. Res. 19:224-234.
280. Zompi, S., J.A. Hamerman, K. Ogasawara, E. Schweighoffer, V.L.J. Tybulewicz, J.P. DiSanto, L.L. Lanier, and F. Colucci. 2003. NKG2D triggers cytotoxicity in mouse NK cells lacking DAP12 or Syk family kinases. Nat. Immunol. 4:565-572.
281. Arase, H. and L.L. Lanier. 2004. Specific recognition of virus-infected cells by paired NK receptors. Rev. Med. Virol. 14:83-93.
282. Hamerman, J.A., K. Ogasawara, and L.L. Lanier. 2004. Cutting Edge: Toll-like receptor signaling in macrophages induces ligands for the NKG2D receptor. J. Immunol. 172:2001-2005.
283. Shiratori, I., K. Ogasawara, T. Saito, L.L. Lanier, and H. Arase. 2004. Activation of natural killer cells and dendritic cells upon recognition of a novel CD99-like ligand by paired immunoglobulin-like type 2 receptor. J. Exp. Med. 199:525-533.
284. Lanier. L.L. 2005. Human NK Receptors and their MHC Ligands. In: HLA 2004: Immunobiology of the Human MHC. Proceedings of the 13th International Histocompatibility Workshop and Conference, Seattle, WA: IHWG Press, J Hansen and B Dupont, Eds. In press.
285. Rosen, D.B. M. Araki, J.A. Hamerman, T. Chen, T. Yamamura, and L.L. Lanier. 2004. A structural basis for the association of DAP12 with mouse, but not human, NKG2D. J. Immunol. 173:2470-2478.
286. Tahara-Hanaoka, S., K. Shibuya, Y. Onoda, H. Zhang, S. Yamazaki, A. Miyamoto, S-I. Honda, L.L. Lanier, and A. Shibuya. 2004. Functional characterization of DNAM-1 (CD226) interaction with its ligands PVR (CD155) and nectin-2 (PRR-2/CD112). Int. Immunol. 16:533-538.
287. Lanier, L.L. 2005. NKG2D in innate and adaptive immunity. Adv. Exp. Med. Biol. 560:51-56.
288. Trinchieri, G. and L.L. Lanier. 2005. Functions of Natural Killer cells. In: Williams' Hematology 7th Ed., E. Beutler et al. ed., McGraw Hill, Chapter 79, p. 1077-1082.
289. Mócsai, A., M.B. Humphrey, J.A.G. Van Ziffle, Y. Hu, A. Burghardt, S.C. Spusta, S. Majumdar, L.L. Lanier, C.A. Lowell, and M.C. Nakamura. 2004. The immunomodulatory adapter proteins DAP12 and Fc receptor γ-chain (FcR) regulate development of functional osteoclasts through the Syk tyrosine kinase. Proc. Natl. Acad. Sci. USA, 101:6158-6163.
290. Ogasawara, K., J.A. Hamerman, L.R. Ehrlich, H. Bour-Jordon, P. Santamaria, J.A. Bluestone, and L.L. Lanier. 2004. NKG2D blockade prevents autoimmune diabetes in NOD mice. Immunity 20:757-767.
291. Lanier, L.L. 2004. NKG2D. J. Biol. Regul. Homeost. Agents 17:338-340.
292. Zingoni, A., T. Sornasse, B.G. Cocks, Y. Tanaka, A. Santoni, and L.L. Lanier. 2005. NK cell regulation of T cell-mediated responses. Mol. Immunol. 42:451-454.
293. Takaki, R., and L.L. Lanier. 2005. Immune surveillance in cancer. In: Viral and Immunological Malignancies, P.A. Volberding and J. Palefsky, eds. BC Decker Inc. Publisher, Hamilton, Ontario, Canada, Chapter 3.
294. Zingoni, A., T. Sornasse, B.G. Cocks, Y. Tanaka, A. Santoni, and L.L. Lanier. 2004. Cross-talk between activated human NK cells and CD4+ T cells via OX40-OX40 ligand interactions. J. Immunol. 173:3716-3724.
295. Lodoen, M.B. and L.L. Lanier. 2005. Viral modulation of NK cell immunity. Nat. Rev. Microbiol. 3:59-69.
296. Meresse, B., Z. Chen, C. Ciszewski, M. Tretiakova, G. Bhagut, T.N. Krausz, D.H. Raulet, L.L. Lanier, V. Groh, T. Spies, E.C. Ebert, P.H. Green, and B. Jabri. 2004. Coordinated induction by IL15 of a TCR-independent NKG2D signaling pathway converts CTL into lymphokine-activated killer cells in celiac disease. Immunity 21:357-366.
297. Voehringer, D., D.B. Rosen, L.L. Lanier, and R.M. Locksley. 2004. CD200 receptor family members represent novel DAP12-associated activating receptors on basophils and mast cells. J. Biol. Chem. 279:54117-54123.
298. Hamerman, J.A., K. Ogasawara, and L.L. Lanier. 2005. NK cells in innate immunity. Curr. Opin. Immunol. 17:29-35.
299. Lodoen, M.B., G. Abenes, S. Umamoto, J.P. Houchins, F. Liu, and L.L. Lanier. 2004. The cytomegalovirus m155 gene product subverts natural killer cell antiviral protection by disruption of H60-NKG2D interactions. J. Exp. Med. 200:1075-1081.
300. Lanier, L.L. 2005. NK cell recognition. Annu. Review Immunol. 23:225-274.
301. Richie Ehrlich, L.I., K. Ogasawara, J.A. Hamerman, R. Takaki, A. Zingoni, J.P. Allison, and L.L. Lanier. 2005. Engagement of NKG2D by cognate ligand or antibody alone is insufficient to mediate costimulation of human and mouse CD8+ T cells. J. Immunol. 174:1922-1931.
302. Bach, J-F., A. Bendelac, M.B. Brenner, H. Cantor, G. De Libero, M. Kronenberg, L.L. Lanier, D.H. Raulet, M.J. Shlomchik, and M.G. von Herrath. 2004. The role of innate immunity in autoimmunity. J. Exp. Med. 200:1527-1531.
303. Lanier, L.L. 2005. First sighting of the elusive T cell antigen receptor. J. Immunol. 174:1143.
304. Hamerman, J.A., N. K. Tchao, C.A. Lowell, and L.L. Lanier. 2005. Enhanced Toll-like receptor responses in the absence of signaling adaptor DAP12. Nat. Immunol. 6:579-586.
305. Lanier, L.L. 2005. Missing self, NK cells and the White Album. J. Immunol. 174:6565.
306. Desrosiers, M-P., A. Kielczewska, J-C. Loredo-Osti, S.G. Adam, A.P. Makrigiannis, S. Lemieux, T. Pham, M.B. Lodoen, K. Morgan, L.L. Lanier, and S.M. Vidal. 2005. Epistasis between Klra and major histocompatibility complex class I loci is associated with a new mechanism of natural killer cell-mediated innate resistance to cytomegalovirus infection. Nat. Genet. 37:593-599.
307. Vidal. S.M., and L.L. Lanier. 2005. NK cell recognition of mouse cytomegalovirus-infected cells. Current Topics in Microbiology and Immunology 298:183-206.
308. Takaki, R., Y. Hayakawa, A. Nelson, P.V. Sivakumar, S. Hughes, M.J. Smyth, and L.L. Lanier. 2005. IL-21 enhances tumor rejection through a NKG2D-dependent mechanism. J. Immunol. 175:2167-2173.
309. Humphrey, M.B., L.L. Lanier, and M.C. Nakamura. 2005. Role of ITAM-containing adapter proteins and their receptors in the immune system and bone. Immunol. Rev. 208:50-65.
310. Shiratori, I., M. Tamaguchi, M. Suzukawa, K. Yamamoto, L.L. Lanier, T. Saito, and H. Arase. 2005. Down-regulation of basophil function by human CD200 and human herpesvirus-8 CD200. J. Immunol. 175:4441-4449.
311. Ogasawara, K., J. Benjamin, R. Takaki, J.H. Phillips, and L.L. Lanier. 2005. Function of NKG2D in natural killer cell-mediated rejection of mouse bone marrow grafts. Nat. Immunol. 6:938-945.
312. Hamerman, J.A. and L.L. Lanier. 2006. Inhibition of immune responses by ITAM-bearing receptors. Science STKE volume 2006, issue 320, pp. re1.
313. Rosen, D.B., J. Bettadapura, M. Alsharifi, P.A. Mathew, H.S. Warren, and L.L. Lanier. 2005. Cutting Edge: Lectin-like transcript-1 is a ligand for the inhibitory human NKR-P1A receptor. J. Immunol. 175:7796-7799.
314. Ogasawara, K. and L.L. Lanier. 2005. NKG2D in NK and T cell-mediated immunity. J. Clin. Immunol. 25:534-540.
315. Humphrey, M.B., M.R. Daws, S.C. Spusta, E.C. Niemi, J.A. Torchia, L.L. Lanier, W.E. Seaman, and M.C. Nakamura. 2006. TREM2, a DAP12-associated receptor, regulates osteoclast differentiation and function. J. Bone Mineral Research 21:237-245.
316. Routes, J.M., S. Ryan, K. Morris, R. Takaki, A. Cerwenka, and L.L. Lanier. 2005. Adenovirus serotype 5 E1A sensitizes tumor cells to NKG2D-dependent NK cell lysis and tumor rejection. J. Exp. Med. 202:1477-1482.
317. Chen, S., H. Kawashima, J.B. Lowe, L.L. Lanier, and M. Fukuda. 2005. Suppression of tumor formation in lymph nodes by L-selectin-mediated natural killer cell recruitment. J. Exp. Med. 202:1679-1689.
318. Bui, J.D., L.N. Carayannopoulos, L.L. Lanier, W.M. Yokoyama, and R.D. Schreiber. 2006. Interferon-dependent downregulation of the NKG2D-ligand H60 on tumors. J. Immunol. 176:905-913.
319. Chan, C., E. Crafton, H-N., Fan, K. Yoshimura, J. Flook, D. Brockstedt, T.W. Dubensky, M.F. Stins, L.L. Lanier, D.M. Pardoll, and F. Housseau. 2006. Innate killer-dendritic cells directly link innate and adaptive immunity. Nature Medicine 12:207-213.
320. Hesslein, D.G.T., R. Takaki, M.L. Hermiston, A. Weiss, and L.L. Lanier. 2006. Dysregulation of signaling pathways in CD45-deficient NK cells leads to differentially regulated cytotoxicity and cytokine production. Proc. Natl. Acad. Sci. USA 103:7012-7017.
321. Lodoen, M. and L.L. Lanier. 2006. NK cells as an initial defense against pathogens. Curr. Opin. Immunol., In press.
322. Shiow, L.R., D.B. Rosen, N. Brdickova, Y. Xu, J. An, L.L. Lanier, J.G. Cyster, and M. Matloubian. 2006. CD69 acts downstream of interferon-α/β to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 440:540-544.
323. Cao, W., D.B. Rosen, T. Ito, L. Bover, M. Bao, G. Watanabe, L. Zhang, L.L. Lanier, and Y-J. Liu. 2006. Plasmacytoid dendritic cell-specific receptor ILT7/FcεRIγ inhibits Toll-like receptor-induced interferon production. J. Exp. Med. 203:1399-1405.
324. Lanier, L.L. 2006. Viral immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling in cell transformation and cancer. Trends in Cell Biology, In press.


Meresse, B., S.A. Curran, C. Ciszewski, G. Orbelyan, M. Setty, G. Bhagat, L. Lee, M. Tretiakova, C. Semrad, E. Kistner, R.J. Winchester, V. Braud, L.L. Lanier, D.E. Geraghty, P.H. Green, S. Guandalini, and B. Jabri. 2006. Reprogramming of CTLs into natural killer-like cells in celiac disease. J. Exp. Med. 203:1343-1355.
326. Hamerman, J.A., J.R. Jarjoura, M.B. Humphrey, M.C. Nakamura, W.E. Seaman, and L.L. Lanier. 2006. Cutting Edge: Inhibition of Toll-like receptor and Fc-receptor responses in macrophages by TREM-2 and DAP12. J. Immunol., In press.
to top
Copyright (c) The 6th Awaji International Forum on Infection and Immunity. All rights reserved.
To do inspection and use comfortably, we are recommending a browser and the environment of the following versions.
Microsoft Internet Explorer 5.x or later version / Netscape Navigator 6.x or later version.
Please set JavaScript to "enable".